Acorda Therapeutics reported $31.47M in Sales Revenues for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Acorda Therapeutics ACOR:US USD 31.47M 2.04M
Amgen AMGN:US USD 6.84B 187M
Arrowhead Research ARWR:US USD 62.55M 30.97M
Biogen BIIB:US USD 2.54B 35.5M
Clovis Oncology CLVS:US USD 30.66M 1.48M
Gilead Sciences GILD:US USD 7.39B 347M
GlaxoSmithKline GSK:LN GBP 7.38B 453M
Heron Therapeutics HRTX:US USD 26.56M 1.07M
Ligand Pharmaceuticals LGND:US USD 50.38M 15.71M
Mannkind MNKD:US USD 72.12M 39.29M
Neurocrine Biosciences NBIX:US USD 412M 24.1M
Novartis NOVN:VX USD 13B 159M
Pfizer PFE:US USD 24.29B 1.65B
Teva Pharmaceutical TEVA:IT USD 3.88B 289M
Ultragenyx Pharmaceutical RARE:US USD 103.35M 12.64M
Vertex Pharmaceuticals VRTX:US USD 2.3B 31.6M